Cardiovascular effects of glucagonlike peptide-1 agonists.

@article{Davidson2011CardiovascularEO,
  title={Cardiovascular effects of glucagonlike peptide-1 agonists.},
  author={Michael H. Davidson},
  journal={The American journal of cardiology},
  year={2011},
  volume={108 3 Suppl},
  pages={33B-41B}
}
Type 2 diabetes mellitus is acknowledged as a major risk factor for the development of cardiovascular disease (CVD). Advancing treatment options for person with diabetes beyond glucose control to prevent microvascular and macrovascular complications and ultimately have an impact on CVD development holds great significance for the growing number of persons… CONTINUE READING